Market Research Blog

[341 Pages Report] According to the latest market report published by Future Market Insights, titled ‘Global Amniotic Membrane Market: Global Industry Analysis 2013 – 2017 and Opportunity Assessment 2018 – 2028’, the global amniotic membrane market is expected to expand at a CAGR of 9.3% over the forecast period 2018–2028.

FMI estimates that the global market for amniotic membrane is to be valued at US$ 955.2 Mn in 2018 and is expected to expand at CAGR of 9.3% over 2018–2028, to surpass US$ 2,322 Mn by 2028 end. Based on product type, the cryopreserved amniotic membrane segment dominated the global amniotic membrane market, with over 70% value share in 2017. The segment is expected to grow at above 9% CAGR over the forecast period of 2018–2028. North America is expected to maintain its dominance in the global market due to regulatory approvals of several new products in the U.S.

Population of all age groups has emerged as a prominent consumer base, characterised by untapped product segments for amniotic membranes to offer effective wound healing and eye surgeries. This has prompted the amniotic membrane product manufacturers to capitalize on the emerging latent opportunity. The companies in the market are optimistic with regard to increasing amniotic membrane transplants and increasing demand for amniotic membrane products around the world, particularly in North American countries. It is more than likely that over the span of the next four to five years, the companies focus on developing innovative products and designing market level strategies to leverage the potential opportunities emerging in parallel with growing human population with various chronic diseases.

Amniotic membrane products such as Amniotic Allograft Membrane and Amniotic Allograft Suspension used to treat surgical wounds and defects of the corneal epithelia have gained traction over the last two decades. The major types of amniotic membranes such as cryopreserved amniotic membrane and lyophilized amniotic membrane have evolved back in the 1990s, but they became significant and the market for amniotic membranes to be used on humans boomed over the past fifteen years.

The global amniotic membrane market has been segmented on the basis of product type, application, end user and regions. Globally, cryopreserved amniotic membrane is the most attractive segment from manufacturers’ point of view. Cryopreserved amniotic membrane is majorly used in ocular surface eye surgery owing to its positive effect on wound healing due to its anti-inflammatory property. Among all end users of amniotic membrane, high demand for amniotic membrane is expected to come from the hospitals segment due to rising application of amniotic membrane in advanced surgical healing.

By volume, the global amniotic membrane market is expected to expand at 11.4% over the forecast period of 2018–2028. With nearly 43% market value share, North America dominated the global amniotic membrane market in 2017, partly due to penetration of newly approved products in the U.S. Western Europe, the second large market globally, with U.K., France and Germany being countries with high growth rates., is expected to gain 110 BPS in its market share over 2018–2028. APEJ is expected to be the third large market for amniotic membrane. APEJ and China collectively are expected to contribute over 15% share in the global market by 2028 over 2018.

The market for amniotic membrane is highly consolidated with top 5 players contributing over 60% of the revenue share in 2017. Examples of some of the key players identified in the global market are Integra LifeSciencesm Inc., MiMedx Group, Inc., Alliqua BioMedical, Inc., Skye Biologics Inc., Katena Products, Inc., Tissue-Tech Inc., Amnio Technology, LLC, Applied Biologics LLC, Human Regenerative Technologies, LLC, etc. Depth of research, along with proper documentation and statistical validation are factors that could determine a player’s success in the global amniotic membrane market

To remain ahead of your competitors, request for a sample – https://www.futuremarketinsights.com/reports/sample/rep-gb-5044

Some of the key points identified in global amniotic membrane market are:

• FMI forecasts the global amniotic membrane market to grow at a CAGR of 9.3% over the forecast period by 2028 end. The growth in revenue generation across the amniotic membrane market is registered on the account of rise in amniotic membrane transplants in both developed and developing economies.
• The hospitals segment has proved to be the leading end user segment on account of increase in number of amniotic membrane transplants, growing awareness among the people about the benefits of the amniotic membrane transplant.
• Ease of FDA approval for novel and innovative amniotic membrane allografts coupled with adoption of amniotic membrane for varied applications would boost the revenue growth in Germany & the U.S. markets.
• Most often, apart from major applications including surgical wound and ophthalmology, the use of amniotic tissue in orthopaedic surgery, sports medicine and podiatry treatment has increased in the recent years.
• The amniotic membranes used majorly to treat human surgical wound needs to be FDA approved, thus amniotic membrane manufacturers focus on getting fast FDA approvals.

Market segmentation

The Global Amniotic Membrane Market has been Segmented Based on:

• Product Type
• Application
• End User
• Region

The report analyses the global amniotic membrane market in terms of value (US$ Mn). The report begins with the market definition and explaining different types of amniotic membrane types available in the market. This section also provides an overview on dermal substitute market, to which amniotic membrane is a sub-part. The market view point section includes FMI’s analysis on key trends, drivers, opportunities and macro factors influencing the global market. Opportunity analysis provided in the section allows to better equip with crystal clear decision-making insights. Pipeline analysis provided in the subsequent section helps to identify future rivals in the global market.

The report analyses the market based on regions and presents the forecast in terms of value (US$ Mn) for the next 10 years. The regions covered in the report include:

• North America
• Latin America
• Western Europe
• Eastern Europe
• Asia Pacific Excluding Japan & China (APEJC)
• Japan
• China
• The Middle East and Africa (MEA)

The next section of report analyses the market based on product types and forecast is provided in terms of value for the next 10 years. The product types covered in the report include:

• Cryopreserved Amniotic Membrane
• Lyophilized Amniotic Membrane

The next section of the report provides analysis based on application and the forecast is provided in terms of value for the next 10 years. The applications covered in the report include:

• Surgical Wound
• Ophthalmology
• Others

Get a Tailored Made Report to Match Your requirements, Ask from Market Research Expert – https://www.futuremarketinsights.com/ask-question/rep-gb-5044

The next section of report analyses the market based on the end users of amniotic membrane products and provides the forecast in terms of value for the next 10 years. End users covered in the report include:

• Hospitals
• Specialized Clinics
• Ambulatory Surgical Centres
• Academic Research Centres

Increasing aging population and rise in plastic surgery are the major factor which is fueling the growth of extremity tissue expanders market over the forecast period. According to a latest research by company, the global extremity tissue expanders market is anticipated to account for US$ 1,842.6 Mn, in terms of value, by 2028 end. The report on extremity tissue expanders further projects significant growth potential with average year-on-year growth rate pegged at 6.3% over the period of 2018-2028.

A recently released global market intelligence outlook on sustained release excipients forecasts the revenue through sustained release excipients to surpass a million dollar value by this year’s end, of which just-under 1/3^rd share belongs to North America.

As a growing number of existing international patents are expiring and the prevalence of orthopedic disorders is increasing on the flipside, drug formulations and thereby sustained release excipients are constantly witnessing an impressive manufacturing outlook.

Research identifies the largest revenue shareholding categories in sustained release excipients marketplace on the basis of product type, end user, and route of administration.

• Polymer is currently the largest product type category worth US$ 300 Mn, whereas gelatin represents the most opportunistic one.
• While oral route of administration remains highly sought after, injectable is presumed to gradually take over.
• Biopharmaceutical companies and CMOs pose fierce competition to pharmaceutical companies – the dominant end user of sustained release excipients.

To remain ahead of your competitors, request for a sample – https://www.futuremarketinsights.com/reports/sample/rep-gb-7580

“The top five players leading the competition in global sustained release excipients landscape account for a collective revenue share of over 50%, whereas a number of relatively small companies represent the rest. A majority of competitors have a limited offering portfolio and significantly depend on product differentiation for an edge in niche treatment areas,” explains a senior research analyst. “Product innovation and market expansion have been the top developmental strategies of companies so far, which are now complemented with strategic partnerships,” the analyst adds further.

Multi-level Partnerships – The Key to Delivering Top Notch Excipient Formulations

FMI underlines the critical role of strategic collaborations – between formulators of sustained release excipients and stakeholders across the value chain – in shaping growth of brands as well as the entire sustained release excipients ecosystem.

While partnerships are expected to prominently focus on spotting the key challenges facing manufacturers, continued education about functionality, variability, and consistency of sustained release excipients is also be an important objective. Drug product manufacturers working in tandem with formulators of sustained release excipients is helping companies deliver best-in-class solutions addressing the most prominent pull factors associated with sustained release excipients.

To best grasp real-time market needs, sustained release excipient formulators are most likely to strengthen interaction with end-use customers. This move offers a dual advantage as a developmental strategy – by helping manufacturers precisely understand and address the challenges facing pharmaceutical markets and stimulating development of new excipient formulations that tap into evolving needs.

A recent deal (2017) involving the combination of The Dow Chemical Company-DuPont-FMC (Health & Nutrition) has been a classic example of collaborative operation, involving channel partners as well as customers.

Segmentation

The report offers a comprehensive taxonomy of sustained release excipients market based on product type, end user, route of administration route, and region. The sustained release excipients are sold for various types of test samples, such as blood, skin, etc. These sustained release excipients are used by pharmaceutical companies, biopharmaceutical companies, neutraceutical companies, and for various type of sustained release excipients, such as food allergies, drug allergies, latex allergies and other types of allergies.

End-use segments in the sustained release excipients market which are a part of this sustained release excipients market report include pharmaceutical companies, biopharmaceutical companies and other end users, such as nutraceutical manufacturers and contract manufacturing organisations. The sustained release excipients market has been analyzed across regions of North America, Latin America, Europe, CIS & Russia, Asia Pacific and MEA.

Get a Tailored Made Report to Match Your requirements, Ask from Market Research Expert – https://www.futuremarketinsights.com/ask-question/rep-gb-7580

Biopsy is defined as a procedure that is performed for removing cells or tissue from the patient’s body for further examination under a microscope. Lung Biopsy includes the extraction of samples of lung tissues for the determination of any lung disease like lung cancer. Lung biopsy systems are designed for either an open lung biopsy or closed lung biopsy. Closed methods are usually performed through the windpipe (trachea) or through the skin, wherein, an open biopsy is performed under general anesthesia in an operating room. Lung biopsy systems are required for performing lung biopsy for determination of various lung-related issues, and is recommended after abnormalities in the chest are found post chest x-ray or a computerized tomography scan. Post determination, lung biopsy systems are also helpful in determining what stage of lung cancer it is in a patient. Diagnosing lung cancer in its initial stages might help in decreasing the mortality rates. As per the American Cancer Society, the number of incidence cases for lung cancer were approximately around 228,150 for 2019 in the United States. This increasing incidence demands the urgency of more efficient, less invasive, and accurate diagnostic systems like lung biopsy systems across regions. Lung biopsy systems are recognized as one of the most essential tools for diagnosis as well as for the treatment of lung cancer.

Lung Biopsy Systems Market: Drivers and Restraints-

Incidence of lung cancer has been rising in the higher income countries owing it to the growing unhealthy lifestyle trend. This rise in lung cancer cases is expected to propel demand for lung biopsy systems for detection and treatment of lung cancer, which is expected to further fuel market growth for lung biopsy systems during the forecast period. Several combination lung biopsy systems and technological advancements for lung biopsy systems is also expected to contribute to boost the market growth for lung biopsy systems during the forecast period. Increase in healthcare expenditure around the globe and growth of medical devices industry across region could also favor the lung biopsy systems market growth over the forecast period. However, high costs associated with lung biopsy systems and lack of awareness of lung biopsy systems in low economy regions might hamper market growth for lung biopsy systems over the forecast period.

Lung Biopsy Systems Market: Region-wise Outlook

North America and Europe’s lung biopsy systems market is expected to propel major growth of the global lung biopsy systems market, owing it to the innovations and product approvals of these systems for lung cancer screening.  High prevalence rates of lung cancer and increasing number of lung biopsy systems manufacturers in these regions is also expected to boost demand for lung biopsy systems in the region. Asia-pacific market for lung biopsy systems, majorly, Japan, China, and Korea are expected to increase significantly during the forecast period, because of the growing awareness on lung cancer, rise in geriatric population and high incidence rates due to increased lifespan in these regions.

Lung Biopsy Systems Market: Key Market Participants

Some of the market participants in the Global Lung Biopsy Systems market identified across the value chain include: BD, Medtronic, DTR Medical, B. Braun Melsungen AG, Argon Medical Devices, Cardinal Health, Hologic, Inc., Fujifilm Medical Systems, and Olympus Corporation.

The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to market segments such as geographies, application, and industry.

To remain ahead of your competitors, request for a sample – https://www.futuremarketinsights.com/reports/sample/rep-gb-9349

The report covers exhaust analysis on:

• Market Segments
• Market Dynamics
• Market Size
• Supply & Demand
• Current Trends/Issues/Challenges
• Competition & Companies involved
• Technology
• Value Chain

Regional analysis includes:

• North America (U.S., Canada)
• Latin America (Mexico. Brazil)
• Western Europe (Germany, Italy, France, U.K, Spain)
• Eastern Europe (Poland, Russia)
• Asia Pacific (India, ASEAN, Australia & New Zealand)
• China
• Japan
• Middle East and Africa (GCC Countries, S. Africa, Northern Africa)

Lung Biopsy Systems Market: Segmentation

Paediatric Spasticity Treatment: Market Insights 

Paediatric Spasticity results due to damage of portion of brain or spinal cord which controls the voluntary movement. When paediatric spasticity occurs due to injury or disease, nerve signals do not reach muscles and continuously contract which causes stiffness and tightness which interfere with movement and speech. Several drugs are available to treat the Paediatric Spasticity, drugs are injected into the affected nerve or the muscle. Physical therapy used to increase strength, improve muscle mobility and muscle coordination, use of braces, and electrical stimulation. Oral medication for treatment of paediatric spasticity is considered when spasticity symptoms gets adverse and start affecting daily muscle functioning. According to estimates from CDC’s Autism and Developmental Disabilities Monitoring (ADDM) Network, about 1 in 323 children has been identified with Cerebral Palsy and most (77.4%) of the children identified with CP had spastic CP.

Paediatric Spasticity Treatment: Market Dynamics

Increasing awareness, growing research and development for drug development drive the market of paediatric spasticity treatment in the near future. Changing lifestyle, developing new and innovative technology, improving healthcare infrastructure is expected to fuel the paediatric spasticity treatment market in the forecast period. Launch of novel therapeutics and growing per capita income in the emerging economies such as China, Brazil is further drive the paediatric spasticity treatment market.

Despite many factors which drive the global market for paediatric spasticity treatment, various factor which might hinder the growth of paediatric spasticity treatment market include high cost of treatment and low awareness in under developed and developing countries and rigorous regulations for the approval of drug.

Paediatric Spasticity Treatment: Overview

Advancement and development of new therapeutic treatment and growing clinical trials for the paediatric spasticity treatment creates huge opportunity for the paediatric spasticity treatment market to grow in the forecast period. Collaboration and partnership among major players for developing new drugs, increasing funding for the research will drive the market of paediatric spasticity treatment in near future. For instance, in august 2016, FDA Approved Ipsen’s Dysport (abobotulinumtoxina) injection for the treatment of lower limb spasticity in children aged two and older.

To remain ahead of your competitors, request for a sample – https://www.futuremarketinsights.com/reports/sample/rep-gb-9408

Paediatric Spasticity Treatment: Region-wise Outlook

The North America is expected to contribute to a major share in the global paediatric spasticity treatment, owing to increasing population, increasing number of screening procedures, presence of major manufacturers and growing clinical trials. Well-developed healthcare facilities and government funding for drug development further drive the market for paediatric spasticity treatment. Europe contributes for the second largest share with significant growth in the global paediatric spasticity treatment market owing to technological advancement in the treatment coupled with growing adoption of new treatment. Asia Pacific market is primarily driven by the factors such as growing prevalence, increasing population, growing awareness of new treatment options. China is expected to register rapid growth in the paediatric spasticity treatment market, due to large patient pool, availability of new drugs for the paediatric spasticity treatment. Latin America and Middle East & Africa are projected to show sluggish growth in paediatric spasticity treatment market, due to less awareness, lack of adequate healthcare facilities and less developed infrastructure.

Pediatric Spasticity Treatment: Key Players

Some of the key players present in the global pediatric spasticity treatment market are Allergan plc, Ipsen Biopharmaceuticals, Inc., Almirall, S.A, Piramal Critical Care, Inc., Genentech, Inc, Sanofi, Saol Therapeutics, US WorldMeds, LLC among others.

The report covers exhaustive analysis on,

• Pediatric Spasticity Treatment Market Segments
• Pediatric Spasticity Treatment Market Dynamics
• Historical Actual Market Size, 2012 – 2016
• Pediatric Spasticity Treatment Market Size & Forecast 2016 to 2024
• Pediatric Spasticity Treatment Market Current Trends/Issues/Challenges
• Competition & Companies involved
• Pediatric Spasticity Treatment Market Drivers and Restraints

Regional analysis includes

• North America
• Latin America
• Europe
• Asia Pacific Excluding China
• China
• Middle East & Africa

Pediatric Spasticity Treatment: Segmentation 

The global Pediatric Spasticity Treatment market is segmented on basis of drug type, distribution channel and geography.

Segmentation by Drug Type

• Baclofen or Muscle Relaxants
• Botox
• Intrathecal Baclofen
• Clonazepam
• Diazepam
• Tizanidine
• Others

Segmentation by Route Of Administration

• Oral
• Injectable

Get a Tailored Made Report to Match Your requirements, Ask from Market Research Expert – https://www.futuremarketinsights.com/ask-question/rep-gb-9408

Segmentation by Distribution Channel

• Hospitals Pharmacies
• Drug Stores
• Retail Pharmacies
• Mail Order Pharmacies

One of the biggest public growing threat called mosquito-borne infections is booming worldwide with over one million deaths every year. Infections transmitted through travels and environmental changes possess a strong impact and has increased considerably over the years. Mosquito-borne infections are caused by bacteria, viruses, or parasites transmitted by mosquitoes. Mosquito-borne infections testing is generally differentiated based on the type of infections namely: mosquito-borne infections testing for dengue, mosquito-borne infections testing for zika virus, mosquito-borne infections testing for chikungunya, and mosquito-borne infections testing for malaria. Mosquito-borne infections testing is considered as the primary mode of diagnosis for mosquito-borne infections. Mosquito-borne infections testing is easily available at healthcare facilities. There are multiple mosquito-borne infections which show similar symptoms like muscle and joint pain and febrile illness.

Mosquito-borne infections Testing Market: Drivers and Restraints

The increasing prevalence of malaria, dengue and chikungunya are anticipated to be the prime factor in boosting the growth of the global mosquito-borne infections testing market over the forecast period. The incidence of dengue has grown dramatically across the globe in recent years. According to WHO, the number of cases increased from 2.2 million in 2010 to 3.2 million in 2015. Furthermore, growing infections surveillance efforts undertaken by U.S. Food and Drug Administration (FDA) and U.S. Department of Health and Human Services (HHS) is expected to fuel the market for mosquito-borne infections testing in the U.S. However, lack of awareness in low middle-income economies is expected to hamper the growth of the global mosquito-borne infections testing market. Lack of awareness can be concerning for individuals who are more susceptible to infections. Vector Disease Control International (VCDI) spread awareness throughout the U.S. about the dangers of mosquito-borne infections and importance of mosquito-borne infections testing. These all factors are responsible in boosting and hampering the growth of the global mosquito-borne infections testing market.

Mosquito-borne infections Testing Market: Regional Outlook

On the basis of geography, the global mosquito-borne infections testing market is segmented into eight key regions, namely North America, Latin America, Western Europe, Eastern Europe, Asia Pacific excluding China and Japan, China, Japan, and Middle East & Africa. North America is expected to contribute the maximum market share in the global mosquito-borne infections testing market due to the continuous spread of mosquito-borne infections. According to the CDC, the number of mosquito-borne infections rose from 4,858 in 2004 to 47,461 in 2016 in the U.S. Also, there was a great rise in 2016 when 41,680 Zika virus cases were reported. Latin America mosquito-borne infections testing the market and the Middle East & Africa mosquito-borne infections testing market is expected to contribute significant market share in the global mosquito-borne infections testing the market.

Mosquito-borne infections Testing Market: Key Players

Examples of some of the key players in the global mosquito-borne infections testing market are InBios International Inc, NovaTec Immundiagnostica GmbH, Abbott Laboratories, Abnova Corporation, Thermo Fisher Scientific Inc, Certest Biotech SL, F. Hoffmann-La Roche Ltd, OriGene Technologies Inc, Quest Diagnostics, and others.

To remain ahead of your competitors, request for a sample – https://www.futuremarketinsights.com/reports/sample/rep-gb-8636

The report covers exhaustive analysis on:

• Market Segments
• Market Dynamics
• Market Size.
• Current Trends/Issues/Challenges
• Competition & Companies involved
• Value Chain

The regional analysis includes:

• North America (U.S., Canada)
• Latin America (Mexico. Brazil)
• Western Europe (Germany, Italy, France, U.K, Spain, Nordic countries, Belgium, Netherlands, Luxembourg)
• Eastern Europe (Poland, Russia)
• Asia-Pacific Excluding China and Japan (India, ASEAN, Australia & New Zealand)
• China
• Japan
• The Middle East and Africa (GCC, S. Africa, N. Africa)

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macroeconomic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

Mosquito-borne infections Testing Market: Segmentation

The global mosquito-borne infections testing market is segmented by test type, indication, end users and region:

A bovine pericardial valve is an artificial bio-prosthetic cardiac valve with a three-cusp structure made from chemically treated bovine pericardium on a suitable framework such as a titanium frame. A bovine pericardial valve is used to replace a diseased or faulty natural heart valve which allows unidirectional flow of blood.Bovine Pericardial Valve Market: Drivers and Restraints 

The growing demand generated due to the increasing incidence of cardiac and valve diseases owing to the increasing incidence of cardiopathies such as sinus node dysfunction and heart block are the prime drivers of the bovine pericardial valve market. Heart valve disease affects approximately 5 million Americans every year. Risk factors such as infections of the valves, rheumatic fever, heart attack, advanced heart failure or atherosclerosis, high cholesterol, high blood pressure, being overweight, autoimmune disorders including lupus, rheumatoid arthritis and others are driving a large market.

According to the center for disease control and prevention, about 610,000 U.S. citizens die of heart disease each year. Coronary heart disease (CHD) is the major heart disease, resulting in over 370,000 deaths each year. The statistics also point to the fact that about 735,000 Americans suffer from a heart attack per year. Speaking in economic terms, heart disease costs about $200 billion each year to the U.S. exchequer, which includes the cost of health care services, medications, and lost productivity. Thus a large bovine pericardial valve market is well evident even to an untrained eye.

The demographic drivers of the bovine pericardial valve market are growing the older population, sedentary lifestyles leading to obesity, substance abuse, junk food and others. The growing incidence of diseases such as diabetes, hypertension and other autoimmune diseases are other drivers of the market. According to the center for disease control and prevention, almost 70 million Americans representing some 30% of the population suffer from hypertension.

Technological advancements resulting in product development such as the development of customized bovine pericardial valve is driving a faster bovine pericardial valve market adoption. Development of inert materials such as silicon is expected to result in growing functionality and market adoption owing to superior performance.

However, the high cost of the bovine pericardial valve, competition from drug therapy, scarcity of experienced surgeons, the lower per capita income of the developing world and the high risk of surgery is hampering the bovine pericardial valve market.

To remain ahead of your competitors, request for a sample – https://www.futuremarketinsights.com/reports/sample/rep-gb-8654

Bovine Pericardial Valve Market: Regional Wise Outlook

The global Bovine pericardial valve market can be classified into the following region: North America, Latin America, Western Europe, Eastern Europe, Asia-Pacific, Japan, Middle East, and Africa. North America, led by the U.S., is expected to account for the largest share in the global bovine pericardial valve market, owing to the large demand, large healthcare expenditure, and large per capita income in the region.

The Asia Pacific bovine pericardial valve market excluding Japan is projected to expand and dominate the scene in the near future, owing to the growing healthcare and large specialty hospitals.

China and India are anticipated to account for the major share of the Asia Pacific bovine pericardial valve market growth. Germany, France, and the U.K., are projected to be the largest drivers of the Europe Bovine pericardial valve market. The Middle East and Africa Bovine pericardial valve market is anticipated to be dominated by the Gulf economies of Saudi Arabia, Kuwait, UAE and Qatar.

Bovine Pericardial Valve Market: Market Participants

Some of the major vendors operating in the global Bovine pericardial valve market are Edwards Lifesciences, Medtronic, Meril Life Sciences Pvt. Ltd., Boston Scientific Corporation, Labor Laboratórios Ltda., Abbott, Colibri Heart Valve, St. Jude Medical, and others.

The global bovine pericardial valve report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides an in-depth analysis of parent market trends, macroeconomic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

The Bovine Pericardial Valve report covers exhaustive analysis on,

• Market Segments
• Market Dynamics
• Market Size
• Supply & Demand
• Current Trends/Issues/Challenges
• Competition & Companies involved
• Technology
• Value Chain

Regional analysis includes,

• North America (U.S., Canada)
• Latin America (Mexico, Brazil)
• Western Europe (Germany, Italy, U.K., Spain, France, Nordic countries, BENELUX)
• Eastern Europe (Russia, Poland, Rest of Eastern Europe)
• Asia Pacific Excluding Japan (China, India, Australia & New Zealand)
• Japan
• Middle East and Africa (GCC, S. Africa, Rest Of MEA)

Get a Tailored Made Report to Match Your requirements, Ask from Market Research Expert – https://www.futuremarketinsights.com/ask-question/rep-gb-8654

Bovine Pericardial Valve Market: Segmentation 

To gain a bird’s eye view of the global bovine pericardial valve market, the report is segmented on the basis of alloys, valve type, and region.

Based on the alloys, the global bovine pericardial valve market can be segmented as,

• Cobalt-chrome
• Titanium
• Nickel Molybdenum
• Others

Based on the valve type, the global Bovine pericardial valve market can be segmented as,

• Aortic
• Mitral
• Other

Report Highlights:

• Detailed overview of parent market
• Changing market dynamics in the industry
• In-depth market segmentation
• Historical, current and projected market size in terms of volume and value
• Recent industry trends and developments
• Competitive landscape
• Strategies of key players and products offered
• Potential and niche segments, geographical regions exhibiting promising growth
• A neutral perspective on market performance
• Must-have information for market players to sustain and enhance their market footprint

Siemens leads the packs globally, FMI offers an extensive assessment of the competitive landscape of angio suites market for 2018-2028

With an estimated incremental opportunity of more than US$ 100 million over 2018, the global revenue through sales of angio suites is likely to approach US$ 1.9 Bn in 2019. As reported by a new research intelligence study on the global angio suites market, there will be more than 6% year on year revenue growth in 2019 – reflecting a healthy outlook for the angio suites landscape at a global level.

Key Research Insights Drawn from the Report

• In a consolidated market structure, the top three companies operating in the global angio suites landscape hold a whopping revenue share of around 70%.
• Easy, fast-track FDA clearance holds vital importance in shaping the new product developments and launches.
• Innovative therapy suites and angio suites are receiving wider platforms in recent years, with growing government funds and consistently increasing voluntary funds – pushing R&D activities further.

More than 1/4^th Share of the Market Revenue Belongs to Siemens

Siemens AG, reportedly the global leader in angio suites landscape, has been highly active in terms of innovation in recent years.

• The company had announced the launch of two products adding value to its innovative offerings in Nov 2017. Siemens Healthineers unveiled two imaging therapy suites that are intraoperative and possess multi-modality imaging capability. While interventional surgeons and radiologists are continuously striving to discover novel procedures that are highly precise yet rapid and affordable, Siemens’ Angio-MR-CT and Angio-CT therapy suites have been presented as a breakthrough innovative solution.
• Later the same year, the company entered a 10-year contractual partnership with Kingston Hospital NHS Foundation Trust over the supply of all-inclusive Managed Equipment Services (MES) to the trust for a wide range of medical imaging systems.

The other two market leaders include Philips Healthcare and GE Healthcare LLC, which are prominently concentrating on innovative product launches for global expansion and introduction of disruptive technology based systems across developing regional markets.

Explaining the most popular developmental strategies adopted by key companies in angio suites landscape, the FMI analyst says, “The strategic focus of angio suites market players is likely to remain on vertical and horizontal integration. Our research concludes that direct selling strategy is allowing companies to cater to the escalating demand for technically innovated products”. Discussing further about the growing significance of having a strong distribution network, “Key players are also prioritizing a stronger distribution network at a global level. Whereas, development of independent distribution channels for personal selling of angio suites is also identified to be one of the key trends among market players,” says the analyst.

To remain ahead of your competitors, request for a sample – https://www.futuremarketinsights.com/reports/sample/rep-gb-7758

Segmental Analysis: Single Plane Angio Suites and Hospitals Remain Top Performing Segments

• With more than 65% share of the global market revenue, single plane angio suites continue to dominate biplane angio suites, according to the report.
• Although cath labs are likely to demonstrate impressive adoption of angio suites in the near future, hospitals remain the largest end user of angio suites.
• Currently, Asia Pacific accounts for over 45% share of the total market revenue, followed by Europe that holds around 30% share in the market value.

The report projects emergence of lucrative business opportunities in developing regional markets, besides APAC, i.e. MEA and Latin America. While the opportunity assessment of emerging regional markets for angio suites analyses the sales force expansion and third party payer coverage in the regions, remarkable reimbursement support and improving customer care are identified to be the primary factors boosting revenue growth of angio suites market in these regions. In a bid to achieve high operational efficiency, a number of companies are strategizing the shifting of their manufacturing facilities to low-cost production bases in emerging economies of Latin America and APAC.

Segmentation

The report offers a comprehensive taxonomy of the angio suites market on the basis of product type, end user and region. On the basis of product type, the global angio suites market has been segmented into biplane angio suites and single plane angio suites.

On the basis of end user, the global angio suites market has been segmented into hospitals and cath labs. From a geographical perspective, the angio suites market has been segmented into North America, Latin America, Europe, Asia Pacific and Middle East & Africa (MEA).

Get a Tailored Made Report to Match Your requirements, Ask from Market Research Expert – https://www.futuremarketinsights.com/ask-question/rep-gb-7758

[213 Pages Report] With the severe dearth of FDA-approved drugs in the reliable treatment of frontotemporal disorders, frontotemporal disorders treatment continues to underscore the growing significance of disease management. As frontotemporal disorders treatment exclusively includes symptomatic efforts till date, the condition continues to attract research interests worldwide.

The available drugs and other means of frontotemporal disorders treatment do not stop or even decelerate the frontotemporal disorders progression, which further remains a key driving force for the growing demand for frontotemporal disorders treatment.

Frontotemporal disorders are often misdiagnosed as depression, Parkinson’s, Alzheimer’s, or any other psychiatric condition, thereby limiting the scope of adoption of frontotemporal disorders treatment.

Although clinical trials have been producing a number of interventions other than medication, a consistently high rate of clinical trial failure is cited as a significant factor influencing the prospects of frontotemporal disorders treatment in the near future.

The report highlights the critical role of governments as well as non-governmental non-profit organizations in terms of research grants and drug approvals. Expanding incentives for orphan drug development is identified as a prominent factor pushing the revenue growth of frontotemporal disorders treatment landscape.

Demonstrating a moderate growth in the revenue year on year, the global landscape of frontotemporal disorders treatment market is slated to approach the US$ 3 billion mark in 2022. As presented in a newly published research intelligence on the global market scenario of frontotemporal disorders treatment, the revenue growth is predominantly driven by the progressing pace of clinical trials.

Discussing the revelations made by the study, says a senior research analyst at Future Market Insights says, “Although frontotemporal disorders are referred to as a symptomatic condition that has not witnessed a curative treatment as of now, an extensive clinical research targeting the discovery of breakthrough curative treatments is driving the growth of revenue at a steady rate”.

Strategic Collaborations Are Shaping the Competition in Fragmented Market

In a highly fragmented landscape of the global frontotemporal disorders treatment market, almost 70% of the companies offer generics as their key drug offerings. Operated by a large number of prominent international, multinational, and regional players, the market for frontotemporal disorders treatment is recently witnessing a heap of strategic deals, including acquisitions, collaborations, and alliances.

2017 was a year of partnerships for GlaxoSmithKline Plc. The company entered multiple strategic collaborations with giants such as Google and Alimama for improved marketing and advertising results. Further, with an objective to push the new drug discovery platform, GSK also signed a four-year contractual partnership with 23andMe. This deal is more likely to speed up the overall clinical progress in frontotemporal disorders treatment.

Moreover, several companies are constantly taking efforts in introducing new potential drugs post successful clinical trials, in the existing line of frontotemporal disorders treatment.

AstraZeneca plc. has recently inked an agreement with Luye Pharma Group, Ltd. over the licensing and sales of Seroquel and Seroquel XR across China, and the UK, in addition to a few other international markets. The drug is occasionally used to address a set of behavioral problems associated with FTD.

To remain ahead of your competitors, request for a sample – https://www.futuremarketinsights.com/reports/sample/rep-gb-5033

According to the taxonomy analysis of frontotemporal disorders treatment market presented in the report,

• Cognitive enhancers are currently contributing around 80% share in the total market value, securing the position of the most favored drug class incorporated in the treatment of frontotemporal disorders.
• On the other side, behavioral symptom management remains the most preferred type of treatment for patients of frontotemporal disorders, thereby accounting for nearly 60% share of the revenue generated in the global frontotemporal disorders treatment market.
• An extensive analysis of the frontotemporal disorders treatment landscape uncovers that around half of the market value belongs to the retail pharmacy segment, making it the most popular distribution channel for frontotemporal disorder drugs.
• Hospital pharmacies remain the second largest channel of distributioni in the frontotemporal disorders market, says the report.

Frontotemporal Dementia Is Highly Prevalent

Based on the symptomatic indication, frontotemporal dementia (FTD), holding a massive market value share, remains the most common indication among all that continues to capture maximum clinical research interests.

Industry experts project that the rapid development of new FTD therapies will push collaborative activities among clinical research entities, educational institutions, academic laboratories, pharma and biotech centers, and the FDA.

Furthermore, FTD therapeutics are anticipated to witness a major contribution from pharmaceutical companies – eventually boosting the funding and clinical trial scenario.

Western Europe Accounts for the Lion’s Share in Market Value

Western Europe and North America collectively extend more than 55% share in the total market value, the former’s share is however projected to remain higher over the foreseeable future. APEJ, with an attractive revenue contribution at present, is projected to remain a highly lucrative regional market for potential investors in the frontotemporal disorders treatment landscape.

While rapidly growing FTD prevalence and the expanding ongoing clinical trials platform are providing a collective push to frontotemporal disorders treatment market in Western Europe, research estimates rapid emergence of Asian economies owing to increasing sophistication of the region’s healthcare sector and gradually surging awareness about frontotemporal disorders.

Key Segments of Frontotemporal Disorders Treatment Industry Research

By Drug Class:

• Cognitive Enhancers
• Antipsychotics
• Antidepressants
• CNS Stimulants
• Others

Get a Tailored Made Report to Match Your requirements, Ask from Market Research Expert – https://www.futuremarketinsights.com/ask-question/rep-gb-5033

By Treatment:

• Behavioral Symptoms Management
• Psychological Symptoms Management

By Disease Indication:

• Frontotemporal Dementia
• Primary Progressive Aphasia
• Movement Disorders

By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Drug Stores
• Online Pharmacies